Alterity Therapeutics Notifies SEC of Unquoted Securities (ATH)

Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K on June 15, 2026, to provide a notification regarding unquoted securities (ATH). The filing serves as a formal update to the Securities and Exchange Commission (SEC) concerning the company's internal security structure, specifically focusing on securities not traded on a public exchange. This report is incorporated by reference into several of the company’s existing Registration Statements on Form S-8 and Form F-3. While the filing indicates activity related to unquoted securities, it does not detail a new public clinical milestone or a change in corporate strategy. The document was signed by Julian Babarczy, the Chairman of the Board. No specific clinical trial data or upcoming result dates were disclosed in this administrative filing.